Country: Mongolia   -  Stage: 1 & 2


MDR-TB burden: 23 per 100,000
No. of trial sites: 1
Date first patient recruited: September 2014
WHO Fact sheet: Click here
Community Engagement: Click here

 

As one of seven countries in the WHO Western Pacific Region with a high burden of TB, Mongolia was selected as one of the trial countries. In 2018, the estimated incidence rate for TB was 428 per 100,000 population. In 2018, 4,065 TB cases were notified. It is also estimated that 4.3% of new cases and 11% of previously treated cases were MDR/RR-TB. In 2016, MDR/RR-TB treatment was initiated in 241 patients, of which 62% were treated successfully.

The National Centre for Communicable Diseases (NCCD), located in Ulaanbaatar, is the main Mongolian partner for the STREAM trial. This agency is devoted to administering and managing the control, prevention, surveillance, diagnosis, and treatment of communicable diseases. One of their central goals is to reduce the spread of TB and TB-related deaths.

For STREAM Stage 1, a total of 33 participants were enrolled in Mongolia.

Given the successful implementation of Stage 1 in Mongolia the site was an excellent candidate to continue into the second stage of the trial. Mongolia was the first country to recruit patients into Stage 2 and enrolled 130 participants in Stage 2.

 

LKHAGVASUREN BAYARSAIKAN, 22, STREAM STAGE 1, and KHULAN BATSUKH, 24, STREAM STAGE 2 pose for a photograph with STREAM medical team at the National Centre of Infectious Diseases in Alaabaatar, Mongolia, July 2017. NARANGARAV TSEGEEN, Data Manager STEAM Clinical trial, STREAM doctor DOLJINSUREN DALAI, NURSES URANCHIMEG ZAGAL AND OYUNTSETSEG SODNOMDARJAA.(Photo/Javier Galeano, Vital Strategies)
STREAM Lab X-ray Tech UYAGMARJAV LKHAMSUREN works at the National Centre of Infectious Diseases in Alaabaatar, Mongolia, July 2017 .(Photo/Javier Galeano, Vital Strategies)
STREAM Lab Tech KHALTARKHUU works in Liquid Culture lab at the National Centre of Infectious Diseases in Alaabaatar, Mongolia, July 2017 .(Photo/Javier Galeano, Vital Strategies)